

FMHL/SE/BM/ MAY'26

May 18, 2026

BSE Limited  
Department of Corporate Services,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001

**Scrip Code: 523696**

**Subject: Outcome of Board Meeting in accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015 (“SEBI Listing Regulations”) this is to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, May 18, 2026, inter-alia, considered and approved the following: -

**1. Financial Results**

Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026 along with Statement of Assets and Liabilities as on March 31, 2026. M/s B S R & Co. LLP, the Statutory Auditors of the Company have issued an Audit Report with an unmodified opinion on the Standalone and Consolidated Financial Statements.

Accordingly, the standalone and consolidated audited financial results, auditors’ reports, Statement of Assets & Liabilities, and declaration pursuant to Regulation 33(3)(d) of the SEBI Listing Regulations, regarding Unmodified Opinion on the Audited financial results for the financial year ended March 31, 2026 are enclosed herewith.

**2. Adoption of Policies**

- a. The modification in the policy for the determination of Materiality of Events/Information, which also contains the details of persons authorized to determine the Materiality of the Event/Information for the purpose of disclosures to Stock Exchange. The said revised policy has been enclosed herewith.
- b. The updated Policy/Code of Conduct for the prevention of Insider Trading. The said updated policy/Code has also been enclosed herewith.

The Board Meeting commenced at 11:30 AM (IST) and concluded at 03:35 PM (IST).

---

**FORTIS MALAR HOSPITALS LIMITED**

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel: +91 172 5096001 Fax: +91 172 5096002

CIN: L85110PB1989PLC045948 Email: [secretarial.malar@malarhospitals.in](mailto:secretarial.malar@malarhospitals.in)

Website: [www.fortismalarhospital.com](http://www.fortismalarhospital.com)



This is for your information and record please.

The same is also uploaded on the website of the Company.

Thanking You,

**For Fortis Malar Hospitals Limited**

**VINTI VERMA**

Digitally signed by VINTI  
VERMA  
Date: 2026.05.18 15:40:51  
+05'30'

**Vinti Verma**  
**Company Secretary & Compliance Officer**  
**ICSI Membership No. A44528**

Encl.: as above

---

**FORTIS MALAR HOSPITALS LIMITED**

**Regd. Office:** Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 **Tel:** +91 172 5096001 **Fax:** +91 172 5096002

**CIN:** L85110PB1989PLC045948 **Email:** [secretarial.malar@malarhospitals.in](mailto:secretarial.malar@malarhospitals.in)

**Website:** [www.fortismalarhospital.com](http://www.fortismalarhospital.com)

## Independent Auditor's Report

### To the Board of Directors of Fortis Malar Hospitals Limited

### Report on the audit of the Standalone Annual Financial Results

#### Opinion

We have audited the accompanying standalone annual financial results of Fortis Malar Hospitals Limited (hereinafter referred to as the "Company") for the 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2026.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

#### Emphasis of Matter

We draw attention to Note 7 to the standalone annual financial results which explains that consequent to sale of business operations through a slump sale transaction, the Company ceases to have any business operations. While there is no visibility of commencing any new business operations in the future, the Company's management and Board of Directors is currently evaluating various corporate restructuring options for the future possible course of actions for the Company and is progressing with the finalisation of plan. However, the Company believes that it has sufficient cash and cash equivalent and other bank balances to settle its obligations as and when they fall due, and it believes that it would be able to meet its financial requirements for the foreseeable future based on the current cash position and projected cash flows. Accordingly, these standalone annual financial results have been prepared on a going concern basis.

Our opinion is not modified in respect of this matter.

**Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results**

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

**Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report.

**Independent Auditor's Report (Continued)**

**Fortis Malar Hospitals Limited**

However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matter**

- a. The standalone annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Co. LLP

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022



**Varun Kumar Tyagi**

*Partner*

Gurugram

18 May 2026

Membership No.: 518152

UDIN: 26518152XOZXMR6561

## Independent Auditor's Report

### To the Board of Directors of Fortis Malar Hospitals Limited

### Report on the audit of the Consolidated Annual Financial Results

#### Opinion

We have audited the accompanying consolidated annual financial results of Fortis Malar Hospitals Limited (hereinafter referred to as the "Holding Company") and its subsidiary (Holding Company and its subsidiary together referred to as "the Group"), for the year ended 31 March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated annual financial results:

- a. include the annual financial results of the following entities
  1. Fortis Malar Hospitals Limited
  2. Fortis Healthcare Research Foundation (formerly known as Malar Stars Medicare Limited)
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2026.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

#### Emphasis of Matter

- a. We draw attention to Note 7 to the consolidated annual financial results which explains that consequent to sale of business operations through a slump sale transaction, the Holding Company ceases to have any business operations. While there is no visibility of commencing any new business operations in the future, the Holding Company's management and Board of Directors is currently evaluating various corporate restructuring options for the future possible course of actions for the Holding Company and is progressing with the finalisation of plan. However, the Holding Company believes that it has sufficient cash and cash equivalent and other bank balances to settle its obligations as and when they fall due, and it believes that it would be able to meet its financial requirements for the foreseeable future based on the current cash position

**Independent Auditor's Report (Continued)**

**Fortis Malar Hospitals Limited**

and projected cash flows. Accordingly, these consolidated annual financial results have been prepared on a going concern basis.

Our opinion is not modified in respect of this matter.

**Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results**

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

**Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

**Independent Auditor's Report (Continued)**

**Fortis Malar Hospitals Limited**

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Holding Company and such other entity included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

**Other Matter**

- a. The consolidated annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Co. LLP

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022



**Varun Kumar Tyagi**

*Partner*

Gurugram

18 May 2026

Membership No.: 518152

UDIN: 26518152SSVHBB9116

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

*(Rs. in lakhs except equity share data)*

No.	Particulars	Standalone			Standalone			Consolidated			Consolidated		
		Quarter ended		Year ended	Quarter ended		Year ended	Quarter ended		Year ended	Quarter ended		Year ended
		March 31, 2026 (Audited) (Refer note 3)	December 31, 2025 (Unaudited)	March 31, 2025 (Audited) (Refer note 3)	March 31, 2026 (Audited)	March 31, 2025 (Audited)	March 31, 2026 (Audited) (Refer note 3)	December 31, 2025 (Unaudited)	March 31, 2025 (Audited) (Refer note 3)	March 31, 2026 (Audited)	December 31, 2025 (Unaudited)	March 31, 2025 (Audited) (Refer note 3)	March 31, 2026 (Audited)
1	Income												
	a) Grant income	-	-	-	-	-	0.31	-	-	0.25	-	5.11	
	b) Other income (refer note 10)	65.63	52.11	76.73	690.18	271.72	65.63	52.11	76.73	630.18	630.18	271.72	
	<b>Total income</b>	<b>65.63</b>	<b>52.11</b>	<b>76.73</b>	<b>690.18</b>	<b>271.72</b>	<b>65.94</b>	<b>52.36</b>	<b>76.73</b>	<b>635.29</b>	<b>635.29</b>	<b>271.72</b>	
2	Expenses												
	a) Purchase of medical consumables and drugs	-	-	-	-	-	-	-	-	-	-	-	
	b) Changes in inventories of medical consumables and drugs	-	-	-	-	-	-	-	-	-	-	-	
	c) Employee benefits expenses	2.18	2.20	(7.79)	8.78	40.76	3.08	2.20	(7.79)	9.68	9.68	40.76	
	d) Finance costs	-	-	-	-	1.02	-	-	-	-	-	1.02	
	e) Depreciation and amortization expenses	-	-	-	-	-	0.26	-	-	0.25	-	-	
	f) Project expenses	-	-	-	-	-	-	-	-	-	-	-	
	g) Other expenses	51.23	28.90	44.76	142.28	171.35	51.90	30.95	44.86	150.03	2.98	173.13	
	<b>Total expenses</b>	<b>53.41</b>	<b>31.10</b>	<b>36.97</b>	<b>151.06</b>	<b>213.13</b>	<b>55.24</b>	<b>33.40</b>	<b>37.07</b>	<b>162.69</b>	<b>162.69</b>	<b>214.91</b>	
3	<b>Profit / (loss) before exceptional items and taxes (1-2)</b>	<b>12.22</b>	<b>21.01</b>	<b>39.76</b>	<b>479.12</b>	<b>58.59</b>	<b>10.70</b>	<b>18.96</b>	<b>39.66</b>	<b>472.60</b>	<b>472.60</b>	<b>56.81</b>	
4	Exceptional items	-	-	-	-	-	-	-	-	-	-	-	
5	<b>Profit / (loss) after exceptional items and before tax(3+4)</b>	<b>12.22</b>	<b>21.01</b>	<b>39.76</b>	<b>479.12</b>	<b>58.59</b>	<b>10.70</b>	<b>18.96</b>	<b>39.66</b>	<b>472.60</b>	<b>472.60</b>	<b>56.81</b>	
6	Tax expense	15.20	17.42	3.59	58.86	17.59	15.20	17.42	3.61	58.86	58.86	17.61	
	- Current tax	15.20	13.11	3.59	54.55	3.59	15.20	13.11	3.59	54.55	54.55	3.59	
	- Deferred tax charged/ (credit)	-	4.31	-	4.31	14.00	-	4.31	0.02	4.31	4.31	14.02	
7	<b>Profit / (loss) after tax (5-6)</b>	<b>(2.98)</b>	<b>3.59</b>	<b>36.17</b>	<b>420.26</b>	<b>41.00</b>	<b>(4.50)</b>	<b>1.54</b>	<b>36.05</b>	<b>413.74</b>	<b>413.74</b>	<b>39.20</b>	
	Other comprehensive income / (loss) (net of tax) Items that will not be reclassified subsequently to the statement of profit and loss:												
	(a) Remeasurements of defined benefit liability	-	-	-	-	-	-	-	-	-	-	-	
	(b) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	
8	<b>Other comprehensive income / (loss) (net of tax)</b>												
9	<b>Total comprehensive income / (loss) for the period / year (7+8)</b>	<b>(2.98)</b>	<b>3.59</b>	<b>36.17</b>	<b>420.26</b>	<b>41.00</b>	<b>(4.50)</b>	<b>1.54</b>	<b>36.05</b>	<b>413.74</b>	<b>413.74</b>	<b>39.20</b>	
	- Owners of the company	(2.98)	3.59	36.17	420.26	41.00	(4.50)	1.54	36.05	413.74	413.74	39.20	
	- Non-controlling interests	NA	NA	NA	NA	NA	-	-	-	-	-	-	
10	Paid up equity share capital (face value Rs.10 each)	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	
11	Reserves excluding revaluation reserves - other equity	NA	NA	NA	1,540.97	1,120.71	NA	NA	NA	1,558.05	1,558.05	1,145.21	
12	<b>Earnings Per Share (EPS) based on: (7) above (of Rs. 10 each) - (Not annualised in the quarters)</b>												
	- Basic	(0.02)	0.02	0.19	2.24	0.22	(0.02)	0.01	0.19	2.21	2.21	0.21	
	- Diluted	(0.02)	0.02	0.19	2.24	0.22	(0.02)	0.01	0.19	2.21	2.21	0.21	



*Brooklyn*

FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: www.fortismalarhospital.com; Email: secretarial.malar@malarhospitals.in

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31,2026

Notes:

I. STANDALONE AND CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	As at March 31,2026	As at March 31,2025	As at March 31,2026	As at March 31,2025
	(Audited)	(Audited)	(Audited)	(Audited)
<b>ASSETS</b>				
<b>Non-current assets</b>				
(a) Financial assets				
Investment in subsidiary	5.00	5.00	-	-
(b) Other tax assets (net)	44.29	250.73	69.35	272.04
(c) Other non-current assets	0.78	-	0.78	-
<b>Total non-current assets</b>	<b>50.07</b>	<b>255.73</b>	<b>70.13</b>	<b>272.04</b>
<b>Current assets</b>				
(a) Financial assets				
(i) Cash and cash equivalents	85.18	10.80	128.60	20.24
(ii) Bank balances other than cash and cash equivalents	2,341.36	1,759.23	2,341.36	1,759.23
(iii) Other financial assets	1,220.25	1,631.54	1,220.25	1,631.54
(b) Other current assets	-	0.15	-	0.15
<b>Total current assets</b>	<b>3,646.79</b>	<b>3,401.72</b>	<b>3,690.21</b>	<b>3,411.16</b>
<b>Total assets</b>	<b>3,696.86</b>	<b>3,657.45</b>	<b>3,760.34</b>	<b>3,683.20</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
(a) Equity share capital	1,875.70	1,875.70	1,875.70	1,875.70
(b) Other equity	1,540.97	1,120.71	1,558.95	1,145.21
<b>Total equity</b>	<b>3,416.67</b>	<b>2,996.41</b>	<b>3,434.65</b>	<b>3,020.91</b>
<b>Liabilities</b>				
<b>Current liabilities</b>				
(a) Financial liabilities				
(i) Trade payables				
Total outstanding dues of micro enterprises and small enterprises	0.92	-	0.92	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	36.03	433.64	37.75	434.80
(ii) Other financial liabilities	238.83	219.56	238.83	219.65
(b) Other current liabilities	4.41	7.84	48.19	7.84
<b>Total current liabilities</b>	<b>280.19</b>	<b>661.04</b>	<b>325.69</b>	<b>662.29</b>
<b>Total liabilities</b>	<b>280.19</b>	<b>661.04</b>	<b>325.69</b>	<b>662.29</b>
<b>Total equity and liabilities</b>	<b>3,696.86</b>	<b>3,657.45</b>	<b>3,760.34</b>	<b>3,683.20</b>

*Budh*



FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: www.fortismalarhospital.com; Email: secretarial.malar@malarhospitals.in

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31,2026

Notes:

2. STANDALONE AND CONSOLIDATED STATEMENT OF CASH FLOWS

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	Year ended March 31,2026	Year ended March 31,2025	Year ended March 31,2026	Year ended March 31,2025
	(Audited)	(Audited)	(Audited)	(Audited)
<b>Cash flows from operating activities</b>				
Profit before tax for the year	479.12	58.59	472.60	56.81
<i>Adjustments for:</i>				
Interest income	(216.74)	(250.04)	(216.74)	(250.04)
Advance tax written off	-	-	-	0.06
Liabilities/ provisions no longer required written back	(413.44)	(21.68)	(413.44)	(21.68)
<b>Operating (loss) / profit before working capital changes</b>	<b>(151.06)</b>	<b>(213.13)</b>	<b>(157.58)</b>	<b>(214.85)</b>
<i>Movements in working capital:</i>				
Increase in other assets and other financial assets	(0.63)	(1.49)	(0.63)	(1.49)
Decrease in provisions	-	(3.23)	-	(3.23)
Increase /(decrease) in trade payables	16.75	(63.74)	17.31	(63.81)
Increase in other liabilities and financial liabilities	15.84	131.65	59.53	110.35
<b>Cash (used in) / generated from operations</b>	<b>(119.10)</b>	<b>(149.94)</b>	<b>(81.37)</b>	<b>(173.03)</b>
Income taxes refund (net)	147.58	327.02	143.83	327.45
<b>Net cash (used in) / generated from operating activities (A)</b>	<b>28.48</b>	<b>177.08</b>	<b>62.46</b>	<b>154.42</b>
<b>Cash flows from investing activities</b>				
Purchase consideration received from sale of business	-	145.58	-	145.58
Dividend from equity investment	-	180.00	-	-
Investment in Bank deposits (net)	-	(1,627.95)	-	(1,627.95)
Proceeds from bank deposits (net)	465.90	-	465.90	-
Bank balances not considered as cash and cash equivalents	(594.96)	(1,677.49)	(594.96)	(1,677.49)
Interest received	174.96	250.04	174.96	250.04
<b>Net cash generated from /(used in) investing activities (B)</b>	<b>45.90</b>	<b>(2,729.82)</b>	<b>45.90</b>	<b>(2,909.82)</b>
<b>Cash flows from financing activities</b>				
Dividend payment	-	(7,965.24)	-	(7,965.24)
<b>Net cash used in financing activities</b>	<b>-</b>	<b>(7,965.24)</b>	<b>-</b>	<b>(7,965.24)</b>
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>	<b>74.38</b>	<b>(10,517.98)</b>	<b>108.36</b>	<b>(10,720.64)</b>
Cash and cash equivalents at the beginning of the year	10.80	10,528.78	20.24	10,740.88
<b>Cash and cash equivalents at the end of the year</b>	<b>85.18</b>	<b>10.80</b>	<b>128.60</b>	<b>20.24</b>

Page 3 of 4

*Budesh*



Notes:

3 The audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 has been reviewed by the Audit and Risk Management Committee and subsequently approved by the Board of Directors at their respective meeting held on May 18, 2026. The above results for the year ended March 31 2026, have been audited by the Statutory auditors of the Company. The auditors have issued an unmodified audit report. Further, the standalone and consolidated figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review and were not subjected to audit.

4 These audited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

5 The consolidated financial results include the financial results of the Company Fortis Malar Hospitals Limited and the financial results of its subsidiary company Fortis Healthcare Research Foundation (Formerly known as Malar Stars Medicare Limited), (collectively known as "Group").

6 The Group is engaged in the Healthcare Services, which in the context of Indian Accounting Standard (Ind AS) 108 - Operating Segments is considered as the only reportable segment of the Group. Also refer note 7 below.

7 During the year ended March 31, 2024, the Company had entered into Business Transfer Agreement ("BTA") with MGM Healthcare Private Limited ("MGM") for the sale of its business operations pertaining to Malar Hospital, as a going concern, on a slump sale basis. Post the slump sale transaction, the Company ceases to have any business operations. Currently, the management of the Company has no visibility of commencing any new business operations in the future and the Company's management and Board of Directors, in consultation with its legal advisors/ merchant bankers, is evaluating various corporate restructuring options for the future possible course of actions for the Company and is progressing with the finalisation of plan.

The Company's cash and cash equivalent and other bank balances (~Rs 3,458.24 lakhs) would be sufficient to settle its obligations as and when they fall due. Based on the current cash position and projected cash flows, the Company believes that it would be able to meet its financial obligations for the foreseeable future such as ongoing expenses for running the Company, resolving medico legal cases (claim amount:~Rs 649.40 lakhs), VAT appeals (tax demand: ~Rs 254.93 lakhs), GST appeal (tax demand: ~Rs 22.23 lakhs) and Income tax appeal (tax demand ~Rs 198.83 lakhs) which are being contested. As a matter of abundant caution these details are being disclosed herein and should not be construed in any manner as admission of any liability or breach. Any financial exposure in respect of medico legal cases, VAT appeals, GST appeal and Income tax appeal are currently estimated and assessed by management as remote. Accordingly, these standalone and consolidated financial results have been prepared on a going concern basis.

8 During the previous year, the Company had received show cause notices totaling to Rs 22,535.42 lakhs from GST authority for the period from July, 2017 to March, 2024, wherein they had proposed to levy GST on various items including depreciation, employee salaries, exempt healthcare services, interest expenses, trade payables, etc., on which either GST is not leviable or on which GST had already been paid, and also GST authority had proposed to disallow GST input tax credit, which had never been claimed by the Company. Subsequent to the issuance of the show cause notices, the Company has received adjudication orders for all the relevant periods. Against the proposed aggregate demand of Rs. 22,535.42 lakhs for the said periods as per above referred show cause notices, the adjudicated demand has been reduced to Rs. 22.23 lakhs for the period from July, 2017 to March, 2023 with Nil demand for the financial year 2023-24.

The Company has filed appeals against the adjudication orders pertaining to the period July 2017 to March 2023.

9 During the quarter ended June 30, 2025, Malar Stars Medicare Limited, the subsidiary company, filed an application with the Ministry of Corporate Affairs, for conversion into a Section 8 Company, as per the provisions of the Companies Act, 2013. The application has been approved by Ministry of Corporate Affairs and is effective from May 14, 2025. Consequently, the name of the subsidiary company has also been changed from 'Malar Stars Medicare Limited' to 'Malar Star Medicare'. Further, the name of the subsidiary company has been changed from 'Malar Star Medicare' to 'Fortis Healthcare Research Foundation' with effect from August 26, 2025.

10 Pursuant to the notification dated June 11, 2025 issued by the Government of Tamil Nadu, regarding the revision of minimum wage rates, the Company has reversed the provision of Rs 408.20 lakhs towards earlier minimum wages payable. The provision written back has been considered as other income in the standalone and consolidated financial results for the quarter ended June 30, 2025.

11 In light of the acquisition of the controlling stake of Fortis Healthcare Limited ("FHL") by Northern TK Venture Pte Limited ("NTK") ("Acquirer") a wholly owned subsidiary of IHH Healthcare Berhad, Malaysia, a mandatory open offer got triggered for acquisition by NTK of up to 4,894,308 fully paid up equity shares of face value of INR 10 each in the Company, representing 26% of the paid-up equity shares of the Company at a price of Rs. 60.10 per share ("Malar Open Offer") in December 2018. However, in view of order dated December 14, 2018 passed by Hon'ble Supreme Court wherein it was specified that status quo with regard to sale of the controlling stake in Fortis Healthcare Limited to IHH Healthcare Berhad, Malaysia be maintained ("Status Quo Order"), the Mandatory Open offer was kept in abeyance. The Hon'ble Supreme Court vide its final judgment dated September 22, 2022 ("2022 Judgment") disposed of the petitions with certain directions to the Hon'ble High Court of Delhi. Basis legal advice, it is understood that pursuant to the 2022 Judgment, the Status Quo Order, being an interim order, ceases to exist and stands merged with the 2022 Judgment.

On October 16, 2025, the Company made a Disclosure in respect of the announcement made by IHH Healthcare Berhad ("IHH") dated October 16, 2025 on the Malaysian Stock Exchange (i.e. Bursa Malaysia) regarding the Malar Open Offer [open offer price was revised from the original open offer price of INR 60.10 (Indian Rupees Sixty and Ten Paisa only) per Equity Share to INR 17.60 (Indian Rupees Seventeen and Sixty Paisa only), in accordance with the requirements of the SEBI (SAST) Regulations]. Basis announcement made by IHH dated November 11 2025, following the completion of the transfer of Malar Shares from the tendering shareholders to the Acquirer and the completion and settlement of payment to the tendering shareholders of the Company, the Malar Open Offer has been completed on November 10, 2025.

12 These financial results are available on the BSE website (www.bseindia.com) and on the Company's website (www.fortismalarhospital.com).

By Order of the Board  
Fortis Malar Hospitals Limited  
CIN: L85110PB1989PLC045948

Bidesh Chandra Paul  
Whole Time Director  
DIN: 08596135  
Place : Gurugram  
Date: May 18, 2026



**Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements, 2015**

This to certify that the statutory auditors of the Company have issued unmodified opinion on Standalone and Consolidated Annual Financial Statements of the Company for the Financial Year ended March 31, 2026.

For **Fortis Malar Hospitals Limited**



**Bidesh Chandra Paul**  
Whole-time Director  
DIN:08596135  
Place: Gurugram  
Date: May 18, 2026



**Pradeep Kumar Malhotra**  
Chief Financial Officer

Place: Gurugram:  
Date : May 18, 2026

---

**FORTIS MALAR HOSPITALS LIMITED**

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel: +0172-4692222 Fax: +91 172 5096002  
CIN: L85110PB1989PLC045948 Email: [secretarial.malar@malarhospitals.in](mailto:secretarial.malar@malarhospitals.in)  
Website: [www.fortismalarhospital.com](http://www.fortismalarhospital.com)